Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

KYMR

Kymera Therapeutics Inc

Dec 12 • 04:00PM ET

89.68

+1.87 2.13 %

Healthcare • Biotechnology • USA • NASD

Peers: SRRK NRIX ARDX QURE KPTI CRNC RVNC MREO ONCT

| Held by: IWM VTI XBI VB VBK IWO IBB VXF SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.60	Insider Own	17.20%	Shs Outstand	71.74M	Perf Week	34.61%
Market Cap	7.08B	Forward P/E	-	EPS next Y	-3.76	Insider Trans	21.26%	Shs Float	65.45M	Perf Month	41.16%
Enterprise Value	6.66B	PEG	-	EPS next Q	-0.80	Inst Own	100.54%	Short Float	13.27%	Perf Quarter	89.68%
Income	-295.12M	P/S	161.91	EPS this Y	-17.64%	Inst Trans	3.03%	Short Ratio	9.05	Perf Half Y	90.97%
Sales	43.73M	P/B	6.80	EPS next Y	-7.11%	ROA	-27.62%	Short Interest	8.69M	Perf YTD	122.92%
Book/sh	13.19	P/C	14.00	EPS next 5Y	-12.11%	ROE	-32.09%	52W High	103.00 -12.93%	Perf Year	99.07%
Cash/sh	6.41	P/FCF	-	EPS past 3/5Y	-12.62% -26.36%	ROIC	-29.03%	52W Low	19.44 361.20%	Perf 3Y	225.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-13.54% 74.20%	Gross Margin	81.13%	Volatility	9.38% 6.00%	Perf 5Y	80.44%
Dividend TTM	-	EV/Sales	152.26	EPS Y/Y TTM	-54.47%	Oper. Margin	-750.91%	ATR (14)	5.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.38	Sales Y/Y TTM	-50.05%	Profit Margin	-674.81%	RSI (14)	72.36	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	7.38	EPS Q/Q	-14.68%	SMA20	25.01%	Beta	2.22	Target Price	110.86
Payout	-	Debt/Eq	0.09	Sales Q/Q	-26.12%	SMA50	38.95%	Rel Volume	1.94	Prev Close	87.81
Employees	188	LT Debt/Eq	0.07	Earnings	Nov 04 BMO	SMA200	97.78%	Avg Volume	960.00K	Price	89.68
IPO	Aug 21, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-22.13% -87.41%	Trades		Volume	1,863,734	Change	2.13%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-25	Resumed	Guggenheim	Buy	$90
Oct-24-25	Reiterated	B. Riley Securities	Buy	$60 → $80
Oct-21-25	Initiated	Mizuho	Outperform	$81
Sep-18-25	Reiterated	H.C. Wainwright	Buy	$60 → $70
Sep-17-25	Initiated	Barclays	Overweight	$60
Sep-16-25	Initiated	RBC Capital Mkts	Outperform	$70
Jul-30-25	Resumed	B. Riley Securities	Buy	$60
Jul-03-25	Resumed	Morgan Stanley	Overweight	$70
Jun-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$79
Jun-03-25	Upgrade	B. Riley Securities	Neutral → Buy	$60
Jun-02-25	Upgrade	BofA Securities	Neutral → Buy	$51
May-20-25	Resumed	Stifel	Buy	$55
Mar-13-25	Initiated	Citigroup	Buy	$52
Dec-10-24	Initiated	BTIG Research	Buy	$60
Dec-06-24	Initiated	BMO Capital Markets	Market Perform	$55
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$57
Nov-18-24	Initiated	Stephens	Overweight	$65
Sep-09-24	Resumed	Leerink Partners	Outperform	$60
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$65
Apr-22-24	Initiated	Oppenheimer	Outperform	$53

Show Previous Ratings

Dec-12-25 10:30AM	Kymera's Eczema Drug Gets Fast Track Designation in the United States (Zacks)
Dec-11-25 04:01PM	Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis (GlobeNewswire)
Dec-09-25 11:30PM	Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering (GlobeNewswire) -7.87%
02:23PM	Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress (Insider Monkey)
10:43AM	Loading…
10:43AM	KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study (Zacks)
Dec-08-25 04:09PM	Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? (Investor's Business Daily) +41.55%
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
03:10PM	This Drugmaker's Stock Is Soaring Over 40% Monday (Investopedia)
01:07PM	Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:42AM	Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:00AM	Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-05-25 04:01PM	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 (GlobeNewswire)
11:30AM	Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? (Zacks)
11:30AM	Loading…
Dec-04-25 11:30AM	Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-26-25 07:33AM	Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
Nov-25-25 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Nov-24-25 07:00AM	Kymera Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-04-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-03-25 07:26AM	Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-28-25 07:00AM	Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-27-25 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
07:00AM	Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting (GlobeNewswire)
Oct-23-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-01-25 09:38AM	Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline (Zacks)
Sep-17-25 07:00AM	Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses (GlobeNewswire)
Sep-16-25 12:30PM	Kymera initiated at Outperform on potential of lead skin drug (Investing.com)
12:15PM	Loading…
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-07-25 10:08AM	Why Kymera (KYMR) Could Be One of Biotech's Most Interesting Growth Stories? (Insider Monkey)
Sep-03-25 07:00AM	Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary (GlobeNewswire) +6.41%
Aug-27-25 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-12-25 03:04AM	Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com) +5.81%
Aug-11-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -7.24%
07:00AM	Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-25 09:23AM	GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up (Zacks)
09:20AM	Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result (GuruFocus.com)
Aug-06-25 10:00AM	CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Aug-04-25 07:00AM	Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-30-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 09:54AM	Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating (Insider Monkey)
Jul-09-25 06:02AM	Morgan Stanley Puts These 2 Stocks on Its Buy List Heres Why You Should Follow (TipRanks)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-28-25 04:16AM	Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer (Insider Monkey)
Jun-27-25 10:19AM	Kymeras partnerships with Sanofi and Gilead drive value (Investing.com)
Jun-26-25 11:56PM	Kymera Therapeutics Announces Pricing of $250 Million Public Offering (GlobeNewswire)
10:45AM	Kymera weakness a buying opportunity, says Stifel (TipRanks)
09:06AM	Morning Movers: General Mills dips following fourth quarter report (TipRanks)
08:40AM	KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update (Zacks)
Jun-25-25 04:05PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
01:04PM	Gilead eyes Kymeras adhesive cancer drug in $750m deal (Pharmaceutical Technology)
08:07AM	Kymera adds Gilead as research partner, while advancing new candidate with Sanofi (BioPharma Dive)
07:05AM	Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update (GlobeNewswire)
07:00AM	Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders (Business Wire)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-06-25 03:13PM	Kymera Therapeutics Stock Earns 92 RS Rating (Investor's Business Daily)
Jun-05-25 04:16PM	Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial (Barrons.com) +7.68%
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
02:22AM	Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 10:29AM	Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response (Benzinga) +45.51%
07:44AM	Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster. (Barrons.com)
07:00AM	Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
May-30-25 04:01PM	Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 (GlobeNewswire)
May-29-25 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire) +5.03%
May-19-25 12:15PM	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference (GlobeNewswire)
May-10-25 07:00AM	Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:01AM	Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
May-08-25 09:26AM	What To Expect From Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings (GuruFocus.com) +5.70%
May-07-25 07:00AM	Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference (GlobeNewswire)
Apr-25-25 06:03PM	Why Kymera Therapeutics Stock Crushed it This Week (Motley Fool)
Apr-24-25 07:00AM	Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025 (GlobeNewswire) +9.32%
Apr-22-25 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader (GlobeNewswire) +6.04%
Apr-10-25 10:10AM	Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? (Zacks) -6.47%
Apr-09-25 07:00AM	Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer (GlobeNewswire) +13.78%
Feb-28-25 02:15AM	Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
Feb-27-25 08:15AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -14.45%
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-26-25 07:33AM	What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings (GuruFocus.com)
07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-20-25 07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 (GlobeNewswire)
Feb-19-25 09:15AM	NAYA Biosciences Announces Nomination of New Board Members (GlobeNewswire)
Jan-30-25 07:00AM	Kymera Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-15-25 09:38AM	Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? (Zacks) +8.57%
Jan-14-25 01:28PM	Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments (GuruFocus.com) +7.79%
07:00AM	Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs (GlobeNewswire)
Jan-07-25 07:00AM	Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 (GlobeNewswire)
Dec-27-24 04:25PM	Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal (TipRanks)
Nov-26-24 07:00AM	Kymera Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-05-24 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-24 03:07AM	Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 08:40AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-30-24 09:10AM	Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Booth Bruce	Director	Dec 10 '25	Sale	91.73	229,809	21,080,724	686,477	Dec 12 06:37 PM
Booth Bruce	Director	Dec 11 '25	Sale	91.23	6,101	556,594	685,501	Dec 12 06:37 PM
Booth Bruce	Director	Dec 12 '25	Sale	91.04	678	61,725	685,393	Dec 12 06:37 PM
Atlas Venture Opportunity Fund	Director	Dec 12 '25	Proposed Sale	89.68	108	9,685		Dec 12 05:20 PM
Atlas Venture Fund X, L.P.	Director	Dec 12 '25	Proposed Sale	89.68	570	51,118		Dec 12 05:08 PM
Atlas Venture Opportunity Fund	Director	Dec 11 '25	Proposed Sale	87.81	976	85,703		Dec 11 05:13 PM
Atlas Venture Fund X, L.P.	Director	Dec 11 '25	Proposed Sale	87.81	5,125	450,026		Dec 11 05:01 PM
BAKER BROS. ADVISORS LP	Director	Dec 11 '25	Buy	86.00	2,005,813	172,499,918	7,955,916	Dec 11 04:19 PM
Atlas Venture Opportunity Fund	Director	Dec 10 '25	Proposed Sale	89.89	36,769	3,305,165		Dec 10 06:39 PM
Atlas Venture Fund X, L.P.	Director	Dec 10 '25	Proposed Sale	89.89	193,040	17,352,366		Dec 10 06:31 PM
Albers Jeffrey W.	Director	Dec 08 '25	Option Exercise	14.18	5,000	70,900	5,000	Dec 08 06:09 PM
Albers Jeffrey W.	Director	Dec 08 '25	Sale	89.76	5,000	448,823	0	Dec 08 06:09 PM
Mainolfi Nello	Chief Executive Officer	Dec 08 '25	Option Exercise	2.08	100,000	208,000	760,482	Dec 08 06:09 PM
Mainolfi Nello	Chief Executive Officer	Dec 08 '25	Sale	89.17	100,000	8,917,000	660,482	Dec 08 06:09 PM
Gollob Jared	Chief Medical Officer	Dec 08 '25	Option Exercise	5.33	49,307	262,806	159,299	Dec 08 06:09 PM
Gollob Jared	Chief Medical Officer	Dec 08 '25	Sale	88.67	49,307	4,371,833	109,992	Dec 08 06:09 PM
Mainolfi Nello	Officer	Dec 08 '25	Proposed Sale	89.17	100,000	8,917,000		Dec 08 06:05 PM
Jared Gollob	Officer	Dec 08 '25	Proposed Sale	66.62	49,307	3,284,832		Dec 08 06:03 PM
JEFFREY ALBERS	Director	Dec 08 '25	Proposed Sale	66.62	5,000	333,100		Dec 08 06:03 PM
Mainolfi Nello	Chief Executive Officer	Oct 29 '25	Option Exercise	2.08	30,000	62,400	690,482	Oct 29 05:19 PM
Mainolfi Nello	Chief Executive Officer	Oct 29 '25	Sale	60.99	30,000	1,829,737	660,482	Oct 29 05:19 PM
Mainolfi Nello	Officer	Oct 29 '25	Proposed Sale	61.68	30,000	1,850,400		Oct 29 04:03 PM
Gollob Jared	Chief Medical Officer	Oct 15 '25	Option Exercise	1.64	51,209	84,185	169,568	Oct 15 05:28 PM
Gollob Jared	Chief Medical Officer	Oct 15 '25	Sale	61.42	59,576	3,659,254	109,992	Oct 15 05:28 PM
Jared Gollob	Officer	Oct 15 '25	Proposed Sale	58.26	59,576	3,470,898		Oct 15 04:36 PM
Gollob Jared	Chief Medical Officer	Oct 13 '25	Option Exercise	1.66	1,473	2,448	121,473	Oct 14 05:11 PM
Gollob Jared	Chief Medical Officer	Oct 13 '25	Sale	60.00	3,114	186,840	118,359	Oct 14 05:11 PM
Albers Jeffrey W.	Director	Oct 13 '25	Option Exercise	10.34	5,000	51,700	5,000	Oct 14 07:55 AM
Albers Jeffrey W.	Director	Oct 13 '25	Sale	59.19	5,000	295,949	0	Oct 14 07:55 AM
Jared Gollob	Officer	Oct 13 '25	Proposed Sale	57.21	3,114	178,152		Oct 14 07:43 AM
JEFFREY ALBERS	Director	Oct 13 '25	Proposed Sale	57.21	5,000	286,050		Oct 14 07:42 AM
Jacobs Bruce N.	Chief Financial Officer	Sep 17 '25	Option Exercise	2.08	79,220	164,778	306,629	Sep 17 05:16 PM
Jacobs Bruce N.	Chief Financial Officer	Sep 17 '25	Sale	50.00	79,220	3,961,380	227,409	Sep 17 05:16 PM
BRUCE N. JACOBS	Officer	Sep 17 '25	Proposed Sale	48.78	79,220	3,864,352		Sep 17 04:24 PM
Mainolfi Nello	Chief Executive Officer	Sep 16 '25	Option Exercise	2.08	30,000	62,400	690,482	Sep 16 04:11 PM
Mainolfi Nello	Chief Executive Officer	Sep 16 '25	Sale	49.00	30,000	1,470,000	660,482	Sep 16 04:11 PM
Mainolfi Nello	Officer	Sep 16 '25	Proposed Sale	49.00	30,000	1,470,000		Sep 16 04:05 PM
BVF PARTNERS L P/IL	Director	Jun 30 '25	Buy	44.00	317,167	13,955,348	2,798,795	Jul 01 06:41 PM
BAKER BROS. ADVISORS LP	Director	Jun 30 '25	Buy	44.00	655,500	28,842,000	6,117,295	Jun 30 08:15 PM
Ridloff Elena	Director	Jun 11 '25	Option Exercise	20.29	4,500	91,305	4,500	Jun 11 04:47 PM
Ridloff Elena	Director	Jun 11 '25	Sale	50.00	4,500	225,000	0	Jun 11 04:47 PM
ELENA RIDLOFF	Director	Jun 11 '25	Proposed Sale	48.60	4,500	218,700		Jun 11 04:26 PM
Esposito Pamela	Director	Jun 03 '25	Option Exercise	29.55	5,000	147,750	5,000	Jun 03 06:30 PM
Esposito Pamela	Director	Jun 03 '25	Sale	49.04	5,000	245,186	0	Jun 03 06:30 PM
Ridloff Elena	Director	Jun 03 '25	Option Exercise	27.67	12,000	332,040	12,000	Jun 03 06:30 PM
Ridloff Elena	Director	Jun 03 '25	Sale	46.10	12,000	553,200	0	Jun 03 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jun 03 '25	Option Exercise	2.08	30,000	62,400	690,482	Jun 03 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jun 03 '25	Sale	49.00	30,000	1,470,000	660,482	Jun 03 06:30 PM
Albers Jeffrey W.	Director	Jun 03 '25	Option Exercise	10.34	6,349	65,649	6,349	Jun 03 06:30 PM
Albers Jeffrey W.	Director	Jun 03 '25	Sale	49.00	6,349	311,101	0	Jun 03 06:30 PM
Mainolfi Nello	Officer	Jun 03 '25	Proposed Sale	49.00	30,000	1,470,000		Jun 03 04:31 PM
JEFFREY ALBERS	Director	Jun 03 '25	Proposed Sale	43.13	6,349	273,832		Jun 03 04:25 PM
PAMELA ESPOSITO	Director	Jun 03 '25	Proposed Sale	43.13	5,000	215,650		Jun 03 04:25 PM
ELENA RIDLOFF	Director	Jun 03 '25	Proposed Sale	43.13	12,000	517,560		Jun 03 04:24 PM
Chadwick Jeremy G	Chief Operating Officer	May 23 '25	Sale	29.30	2,575	75,436	66,420	May 23 04:30 PM
Chadwick Jeremy G	Officer	May 23 '25	Proposed Sale	30.17	2,575	77,688		May 23 04:20 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 31 '25	Option Exercise	2.08	25,000	52,000	226,886	Apr 01 08:00 AM
Chiniara Ellen	Chief Legal Officer	Mar 03 '25	Sale	30.45	2,241	68,239	80,085	Mar 03 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 03 '25	Sale	30.45	1,383	42,113	67,800	Mar 03 06:30 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 03 '25	Sale	30.45	7,035	214,219	201,886	Mar 03 06:30 PM
Gollob Jared	Chief Medical Officer	Mar 03 '25	Sale	30.45	5,740	174,786	120,000	Mar 03 06:30 PM
Gollob Jared	Officer	Mar 03 '25	Proposed Sale	31.35	5,740	179,949		Mar 03 06:00 PM
Chiniara Ellen	Officer	Mar 03 '25	Proposed Sale	31.35	2,241	70,255		Mar 03 06:00 PM
Chadwick Jeremy G	Officer	Mar 03 '25	Proposed Sale	31.35	1,383	43,357		Mar 03 06:00 PM
Jacobs Bruce N.	Officer	Mar 03 '25	Proposed Sale	31.35	7,035	220,547		Mar 03 06:00 PM
Mainolfi Nello	Chief Executive Officer	Jan 10 '25	Option Exercise	2.08	10,000	20,800	659,959	Jan 13 07:00 AM
Jacobs Bruce N.	Chief Financial Officer	Jan 10 '25	Option Exercise	2.08	10,000	20,800	178,921	Jan 13 07:00 AM
Chiniara Ellen	Chief Legal Officer	Jan 06 '25	Sale	41.75	3,129	130,645	54,826	Jan 06 05:00 PM
Chiniara Ellen	Officer	Jan 06 '25	Proposed Sale	41.59	3,129	130,135		Jan 06 04:30 PM

Open in Screener

SION

Sionna Therapeutics Inc

Dec 12 • 04:00PM ET

42.77

+1.05 2.52 %

Healthcare • Biotechnology • USA • NASD

SION Sionna Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO SCHA VTWO IWC ITOT VTWG BBC

Index	RUT	P/E	-	EPS (ttm)	-1.60	Insider Own	45.16%	Shs Outstand	44.46M	Perf Week	6.16%
Market Cap	1.91B	Forward P/E	-	EPS next Y	-2.25	Insider Trans	-7.78%	Shs Float	24.69M	Perf Month	16.92%
Enterprise Value	1.67B	PEG	-	EPS next Q	-0.54	Inst Own	55.26%	Short Float	11.59%	Perf Quarter	91.71%
Income	-70.68M	P/S	-	EPS this Y	87.34%	Inst Trans	-1.20%	Short Ratio	9.74	Perf Half Y	161.11%
Sales	0.00M	P/B	5.91	EPS next Y	-11.31%	ROA	-26.35%	Short Interest	2.86M	Perf YTD	71.08%
Book/sh	7.23	P/C	7.69	EPS next 5Y	46.10%	ROE	-28.07%	52W High	45.00 -4.96%	Perf Year	-
Cash/sh	5.56	P/FCF	-	EPS past 3/5Y	-23.81% -	ROIC	-21.45%	52W Low	7.26 489.52%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.80% 7.03%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.20%	Oper. Margin	-	ATR (14)	2.72	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.61	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	61.38	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	25.61	EPS Q/Q	20.90%	SMA20	4.14%	Beta	-	Target Price	42.57
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	15.29%	Rel Volume	0.69	Prev Close	41.72
Employees	41	LT Debt/Eq	0.02	Earnings	Nov 05 BMO	SMA200	93.05%	Avg Volume	293.85K	Price	42.77
IPO	Feb 07, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	5.02% -	Trades		Volume	202,925	Change	2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-01-25	Downgrade	RBC Capital Mkts	Sector Perform → Underperform	$24
Nov-19-25	Initiated	BTIG Research	Buy	$50
Sep-03-25	Initiated	RBC Capital Mkts	Sector Perform	$22
Sep-03-25	Initiated	Raymond James	Strong Buy	$45
Mar-04-25	Initiated	TD Cowen	Buy
Mar-04-25	Initiated	Stifel	Buy	$32
Mar-04-25	Initiated	Guggenheim	Buy	$45

Nov-24-25 07:00AM	Sionna Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-14-25 06:00PM	Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com) +7.92%
Nov-05-25 07:00AM	Sionna Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:00AM	Sionna Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com) -5.63%
01:15PM	Loading…
Oct-24-25 01:15PM	Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Oct-21-25 07:00AM	Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis (GlobeNewswire) +31.99%
Oct-01-25 04:05PM	Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-15-25 12:00PM	All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy (Zacks)
Sep-09-25 09:55AM	Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High? (Zacks) +13.32%
Sep-08-25 08:00AM	Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer (GlobeNewswire) -9.92%
Aug-27-25 07:00AM	Sionna Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-25-25 07:00AM	Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis (GlobeNewswire)
Aug-11-25 07:00AM	Sionna Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire) +13.36%
Jun-06-25 11:00AM	Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model (GlobeNewswire) +7.42%
01:54PM	Loading…
Jun-04-25 01:54PM	Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial (Benzinga) +9.12%
07:00AM	Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis (GlobeNewswire)
Jun-03-25 07:00AM	Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 07:00AM	Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference (GlobeNewswire)
May-12-25 07:00AM	Sionna Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-30-25 07:00AM	Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 (GlobeNewswire)
Mar-20-25 07:00AM	Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-15-25 04:43PM	Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:25AM	Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey) -5.04%
Mar-03-25 12:57PM	Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-25-25 05:56AM	Sionna Therapeutics IPO: A strategic shift in the cystic fibrosis market (Pharmaceutical Technology) -13.37%
Feb-24-25 08:00AM	Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-17-25 04:43PM	Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:03PM	Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.04% -8.23%
Feb-06-25 07:51PM	Sionna Therapeutics Prices Upsized Initial Public Offering (GlobeNewswire)
03:13PM	Loading…
03:13PM	Vertex challenger Sionna prices $191M IPO (BioPharma Dive)

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Option Exercise	6.11	10,250	62,628	10,250	Dec 09 04:57 PM
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Sale	40.52	10,250	415,330	0	Dec 09 04:57 PM
JENNIFER R FITZPATRICK	Officer	Dec 05 '25	Proposed Sale	40.88	10,250	419,020		Dec 05 04:27 PM
ORBIMED ADVISORS LLC	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:45 PM
Thompson Peter A.	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:41 PM
OrbiMed Private Investments VI	Shareholder	Nov 24 '25	Proposed Sale	44.38	1,047,770	46,500,033		Nov 24 08:22 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 21 '25	Sale	39.50	25,183	994,728	159,033	Nov 24 05:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 20 '25	Sale	40.13	5,133	205,975	166,642	Nov 24 05:43 PM
RA Capital Healthcare Fund LP	Director	Nov 21 '25	Proposed Sale	43.66	1,210	52,829		Nov 21 04:24 PM
RA Capital Nexus Fund III, L.P	Director	Nov 21 '25	Proposed Sale	43.66	6,440	281,170		Nov 21 04:21 PM
RA Capital Nexus Fund, L.P.	Director	Nov 21 '25	Proposed Sale	43.66	9,924	433,282		Nov 21 04:19 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 21 '25	Proposed Sale	43.66	7,609	332,209		Nov 21 04:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 20 '25	Proposed Sale	38.94	1,313	51,128		Nov 20 04:40 PM
RA Capital Nexus Fund, L.P.	Director	Nov 20 '25	Proposed Sale	38.94	2,023	78,776		Nov 20 04:35 PM
RA Capital Healthcare Fund LP	Director	Nov 20 '25	Proposed Sale	38.94	246	9,579		Nov 20 04:34 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 20 '25	Proposed Sale	38.94	1,551	60,396		Nov 20 04:30 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 17 '25	Sale	40.59	81,987	3,328,081	184,619	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 19 '25	Sale	40.01	47,442	1,898,173	168,193	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 18 '25	Sale	39.57	6,922	273,904	182,527	Nov 19 08:43 PM
RA Capital Healthcare Fund LP	Director	Nov 19 '25	Proposed Sale	39.12	2,278	89,115		Nov 19 05:21 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 19 '25	Proposed Sale	38.41	14,334	550,568		Nov 19 05:16 PM
RA Capital Nexus Fund, L.P.	Director	Nov 19 '25	Proposed Sale	38.41	18,696	718,113		Nov 19 05:10 PM
RA Capital Nexus Fund III, L.P	Director	Nov 19 '25	Proposed Sale	38.41	12,134	466,066		Nov 19 05:04 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 18 '25	Proposed Sale	39.04	2,092	81,671		Nov 18 05:22 PM
RA Capital Nexus Fund, L.P.	Director	Nov 18 '25	Proposed Sale	39.04	2,728	106,501		Nov 18 05:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 18 '25	Proposed Sale	39.04	1,770	69,100		Nov 18 05:09 PM
RA Capital Healthcare Fund LP	Director	Nov 18 '25	Proposed Sale	39.04	332	12,961		Nov 18 04:58 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 17 '25	Proposed Sale	39.93	24,772	989,146		Nov 17 05:12 PM
RA Capital Nexus Fund, L.P.	Director	Nov 17 '25	Proposed Sale	39.93	32,310	1,290,138		Nov 17 05:04 PM
RA Capital Nexus Fund III, L.P	Director	Nov 17 '25	Proposed Sale	39.93	20,969	837,292		Nov 17 04:56 PM
RA Capital Healthcare Fund LP	Director	Nov 17 '25	Proposed Sale	39.93	3,936	157,164		Nov 17 04:46 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 24 '25	Sale	39.50	311,000	12,284,500	219,867	Oct 28 09:05 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 28 '25	Sale	39.58	62,610	2,478,104	209,391	Oct 28 09:05 PM
RA Capital Nexus Fund III, L.P	Director	Oct 28 '25	Proposed Sale	39.45	17,118	675,305		Oct 28 05:13 PM
RA Capital Healthcare Fund LP	Director	Oct 28 '25	Proposed Sale	39.45	3,624	142,967		Oct 28 05:07 PM
RA Capital Nexus Fund, L.P.	Director	Oct 28 '25	Proposed Sale	39.45	31,392	1,238,414		Oct 28 05:05 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Oct 28 '25	Proposed Sale	39.45	10,476	413,278		Oct 28 04:57 PM
RA Capital Nexus Fund, L.P.	Director	Oct 24 '25	Proposed Sale	39.21	122,271	4,794,246		Oct 24 06:05 PM
RA Capital Nexus Fund III, L.P	Director	Oct 24 '25	Proposed Sale	39.21	66,672	2,614,209		Oct 24 06:00 PM
RA Capital Healthcare Fund LP	Director	Oct 24 '25	Proposed Sale	39.21	14,116	553,488		Oct 24 05:53 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Oct 24 '25	Proposed Sale	39.21	107,941	4,232,367		Oct 24 05:39 PM
Cloonan Michael	President & CEO	Oct 21 '25	Option Exercise	6.11	99,800	609,778	580,875	Oct 22 05:39 PM
Cloonan Michael	President & CEO	Oct 21 '25	Sale	36.26	99,800	3,618,560	547,343	Oct 22 05:39 PM
Booth Bruce	Director	Oct 21 '25	Sale	34.22	88,878	3,041,683	686,567	Oct 21 05:12 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 21 '25	Proposed Sale	32.20	15,418	496,460		Oct 21 04:22 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 21 '25	Proposed Sale	32.20	73,460	2,365,412		Oct 21 04:21 PM
MICHAEL CLOONAN	Director	Oct 21 '25	Proposed Sale	32.20	99,800	3,213,560		Oct 21 04:19 PM
Booth Bruce	Director	Oct 16 '25	Sale	32.35	169,260	5,476,168	722,301	Oct 20 09:39 PM
Booth Bruce	Director	Oct 17 '25	Sale	32.37	61,124	1,978,323	711,697	Oct 20 09:39 PM
Booth Bruce	Director	Oct 20 '25	Sale	32.09	55,985	1,796,611	701,985	Oct 20 09:39 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 20 '25	Proposed Sale	31.93	46,273	1,477,497		Oct 20 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 20 '25	Proposed Sale	31.93	9,712	310,104		Oct 20 04:46 PM
Cloonan Michael	President & CEO	Oct 15 '25	Option Exercise	6.11	14,775	90,275	562,118	Oct 17 05:11 PM
Cloonan Michael	President & CEO	Oct 16 '25	Option Exercise	6.11	10,425	63,697	557,568	Oct 17 05:11 PM
Cloonan Michael	President & CEO	Oct 15 '25	Sale	31.11	14,775	459,662	547,343	Oct 17 05:11 PM
Cloonan Michael	President & CEO	Oct 16 '25	Sale	31.51	10,425	328,491	547,343	Oct 17 05:11 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 17 '25	Proposed Sale	32.71	10,604	346,857		Oct 17 04:27 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 17 '25	Proposed Sale	32.72	50,520	1,653,014		Oct 17 04:27 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 16 '25	Proposed Sale	30.91	139,897	4,324,216		Oct 16 05:01 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 16 '25	Proposed Sale	30.91	29,363	907,610		Oct 16 05:00 PM
MICHAEL CLOONAN	Director	Oct 16 '25	Proposed Sale	30.91	200	6,182		Oct 16 04:34 PM
Booth Bruce	Director	Oct 15 '25	Sale	30.61	115,856	3,545,798	751,664	Oct 15 06:33 PM
Booth Bruce	Director	Oct 13 '25	Sale	30.38	58,232	1,769,101	771,867	Oct 15 06:33 PM
Booth Bruce	Director	Oct 10 '25	Sale	29.98	20,238	606,735	781,969	Oct 15 06:33 PM
Booth Bruce	Director	Oct 14 '25	Sale	29.95	606	18,150	771,762	Oct 15 06:33 PM
MICHAEL CLOONAN	Director	Oct 15 '25	Proposed Sale	29.94	25,000	748,500		Oct 15 04:38 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 13 '25	Proposed Sale	29.42	48,130	1,415,985		Oct 14 04:23 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 13 '25	Proposed Sale	29.42	10,102	297,201		Oct 14 04:22 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 10 '25	Proposed Sale	28.35	3,511	99,537		Oct 10 04:24 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 10 '25	Proposed Sale	28.35	16,727	474,210		Oct 10 04:24 PM
Booth Bruce	Director	Oct 03 '25	Sale	30.00	37,746	1,132,380	787,527	Oct 07 05:00 PM
Booth Bruce	Director	Oct 06 '25	Sale	29.95	11,800	353,410	785,480	Oct 07 05:00 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 06 '25	Proposed Sale	30.01	2,047	61,430		Oct 06 04:51 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 06 '25	Proposed Sale	30.01	9,753	292,688		Oct 06 04:51 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 03 '25	Proposed Sale	29.30	6,548	191,856		Oct 03 04:44 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 03 '25	Proposed Sale	29.30	31,198	914,101		Oct 03 04:44 PM
Booth Bruce	Director	Sep 29 '25	Sale	30.09	66,105	1,989,099	796,259	Oct 01 06:04 PM
Booth Bruce	Director	Sep 30 '25	Sale	30.06	12,388	372,383	794,110	Oct 01 06:04 PM
Booth Bruce	Director	Oct 01 '25	Sale	29.95	200	5,990	794,075	Oct 01 06:04 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 01 '25	Proposed Sale	29.41	165	4,853		Oct 01 04:17 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 01 '25	Proposed Sale	29.41	35	1,029		Oct 01 04:17 PM
Atlas Venture Fund XI, LP	Shareholder	Sep 30 '25	Proposed Sale	29.52	10,239	302,255		Sep 30 04:21 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 30 '25	Proposed Sale	29.52	2,149	63,438		Sep 30 04:21 PM
Cloonan Michael	President & CEO	Sep 26 '25	Option Exercise	6.11	17,207	105,135	564,550	Sep 30 04:09 PM
Cloonan Michael	President & CEO	Sep 29 '25	Option Exercise	6.11	7,793	47,615	555,136	Sep 30 04:09 PM
Cloonan Michael	President & CEO	Sep 26 '25	Sale	28.85	17,207	496,346	547,343	Sep 30 04:09 PM
Cloonan Michael	President & CEO	Sep 29 '25	Sale	29.70	7,793	231,451	547,343	Sep 30 04:09 PM
Atlas Venture Fund XI, LP	Shareholder	Sep 29 '25	Proposed Sale	28.94	54,637	1,581,195		Sep 29 04:39 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 29 '25	Proposed Sale	28.94	11,468	331,884		Sep 29 04:39 PM
MICHAEL CLOONAN	Director	Sep 26 '25	Proposed Sale	27.50	25,000	687,500		Sep 26 04:31 PM
Fitzpatrick Jennifer	Chief Legal Officer	Sep 04 '25	Option Exercise	6.11	10,250	62,628	10,250	Sep 05 04:03 PM
Fitzpatrick Jennifer	Chief Legal Officer	Sep 04 '25	Sale	23.12	10,250	236,980	0	Sep 05 04:03 PM
JENNIFER R FITZPATRICK	Officer	Sep 04 '25	Proposed Sale	24.55	10,250	251,638		Sep 04 04:24 PM
Ridloff Elena	CFO & Head of Corp. Dev.	Sep 02 '25	Sale	25.08	8,836	221,607	38,532	Sep 03 05:16 PM
Ridloff Elena	CFO & Head of Corp. Dev.	Aug 29 '25	Sale	25.18	748	18,835	47,368	Sep 03 05:16 PM
Cloonan Michael	President & CEO	Aug 26 '25	Option Exercise	6.11	17,574	107,377	564,917	Aug 28 05:40 PM

KYMR

Kymera Therapeutics Inc

SION

Sionna Therapeutics Inc

Upgrade your FINVIZ experience